Biogen (BIIB) Tops Q2 EPS by 43c, Beats on Revenue; Offers FY26 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $248.93 --0%
Financial Fact:
Income tax expense: 337M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Income tax expense: 337M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q2 EPS of $3.60, $0.43 better than the analyst estimate of $3.17. Revenue for the quarter came in at $2.74 billion versus the consensus estimate of $2.43 billion.
GUIDANCE:
Biogen sees FY2026 EPS of $12.00-$13.00, versus the consensus of $12.72.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Harmony Biosciences (HRMY) Misses Q3 EPS by 30c; Offers Guidance
- Twin Disc (TWIN) Tops Q1 EPS by 13c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
